0000905718-16-001355.txt : 20160419 0000905718-16-001355.hdr.sgml : 20160419 20160419092838 ACCESSION NUMBER: 0000905718-16-001355 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160419 DATE AS OF CHANGE: 20160419 EFFECTIVENESS DATE: 20160419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adgero Biopharmaceuticals Holdings, Inc. CENTRAL INDEX KEY: 0001657598 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-261595 FILM NUMBER: 161578113 BUSINESS ADDRESS: STREET 1: 301 N. HARRISON ST. STREET 2: SUITE 9F #459 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-275-6837 MAIL ADDRESS: STREET 1: 301 N. HARRISON ST. STREET 2: SUITE 9F #459 CITY: PRINCETON STATE: NJ ZIP: 08540 D 1 primary_doc.xml X0707 D LIVE 0001657598 Adgero Biopharmaceuticals Holdings, Inc. 301 N. HARRISON ST. SUITE 9F #459 PRINCETON NJ NEW JERSEY 08540 609-275-6837 DELAWARE None None Corporation true 2015 David P. Hochman 301 N. Harrison St. Suite 9F #459 Princeton NJ NEW JERSEY 08540 Director Frank Pilkiewicz 301 N. Harrison St. Suite 9F #459 Princeton NJ NEW JERSEY 08540 Executive Officer Director Steve Rychnovsky 301 N. Harrison St. Suite 9F #459 Princeton NJ NEW JERSEY 08540 Executive Officer Allen Bloom 301 N. Harrison St. Suite 9F #459 Princeton NJ NEW JERSEY 08540 Director Roman Perez-Soler 301 N. Harrison St. Suite 9F #459 Princeton NJ NEW JERSEY 08540 Director Tim McInerney 301 N. Harrison St. Suite 9F #459 Princeton NJ NEW JERSEY 08540 Director Biotechnology Decline to Disclose 06b false 2016-04-08 false true true true Units consisting of common stock and warrants true At closing, our wholly owned subsidiary merged with and into Adgero Biopharmaceuticals, Inc. (Adgero) with Adgero becoming our wholly-owned subsidiary. Among other merger consideration, Adgero stockholders received shares of our stock. 0 Aegis Capital Corp. 15007 None None 810 SEVENTH AVENUE, 18TH FLOOR NEW YORK NY NEW YORK 10019 All States false 15000000 3024730 11975270 Includes over-allotment option. Reflects only private placement consideration. Includes conversion of certain indebtedness. false 39 1950000 true 0 Placement Agent is entitled to receive 10% cash and 3% expense fees. Assumes maximum offering sold and commissions paid pursuant to over-allotment. Does not include up to 300,000 warrants issuable to Placement Agent. 222000 true Some of the proceeds may be used for general working capital purposes which may include the repayment of certain indebtedness and payment of salaries and other fees to those listed in Item 3, as more fully set forth in the offering materials. false Adgero Biopharmaceuticals Holdings, Inc. /s/ Frank Pilkiewicz Frank Pilkiewicz, PHD President and CEO 2016-04-19